// App-Quantinova.ai

: The effect of tiotropium/olodaterol versus tiotropium on COPD exacerbation rates in patients with/without frequent exacerbation history

Researchers

Presenter

  • Jadwiga Wedzicha

Principal Investigators

  • Roland Buhl

  • Alberto De La Hoz

  • Florian Vo

  • Peter M.A. Calverley

Medical Centers

  • National Heart and Lung Institute, Imperial College London, London, United Kingdom

  • Johannes-Gutenberg Universitat Mainz, Mainz, Germany

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim Am Rhein, Germany

  • Clinical Science Centre, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom.

Locations

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Tiotropium/olodaterol

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Parallel Group

Phase

  • III

Study Id's

  • NCT01431287

  • NCT02296138

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved